Biotechnology & Medical Research

Page 1

BioLegend acquires Antibody Products business unit from Covance Inc

Tuesday, 2 Sep 2014 11:00am EDT

Covance Inc:Acquires shares of Covance Antibody Services Inc., business unit of Covance, located in Dedham, Massachusetts, on Aug. 29.Covance Antibody business unit develops and manufactures antibodies and research reagents for Neuroscience, Immunopathology, Cell Biology, Epitope Tags, and Immunohistochemistry Detection.These products, including In Vitro Diagnostic (IVD) antibodies for IHC, are well-suited to complement and enhance the current selection of BioLegend research reagents.

Actinogen Ltd to acquire Corticrine Limited

Tuesday, 26 Aug 2014 11:00pm EDT

Actinogen Ltd:Says that it has signed a sale and purchase agreement to acquire 100 pct. of Corticrine Ltd, a pharmaceutical company focused on the development of new therapies for Alzheimer’s dementia.

Roche Holding AG and InterMune reaches definitive merger agreement

Sunday, 24 Aug 2014 12:00pm EDT

Roche Holding AG and InterMune Inc:Says that they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of $74.00 per share in an all-cash transaction.Says this corresponds to a total transaction value of $8.3 billion on a fully diluted basis.Says the merger agreement has been approved by the boards of InterMune and Roche.Says under the terms of the merger agreement, Roche will commence a tender offer no later than Aug. 29, 2014, to acquire all outstanding shares of InterMune common stock.Says InterMune will file a recommendation statement containing the unanimous recommendation of the InterMune board that InterMune's shareholders tender their shares to Roche.The transaction is expected to be neutral to core earnings per share in 2015 and accretive from 2016 onwards.The closing of the transaction is expected to take place in 2014.Citi is acting as financial advisor to Roche and Davis Polk & Wardwell LLP is acting as legal counsel to Roche.Centerview Partners and Goldman Sachs are acting as financial advisors to InterMune and Cravath, Swaine & Moore LLP is acting as legal counsel to InterMune.

Clinigen Group PLC acquires Ethyol from AstraZeneca

Wednesday, 20 Aug 2014 02:00am EDT

Clinigen Group PLC:Says acquisition of global rights to oncology support therapy, Ethyol (amifostine) from AstraZeneca.Says Ethyol is a cytoprotective drug indicated as an adjuvant therapy to reduce the incidence of xerostomia (dry mouth) as a side-effect in patients undergoing post-operative radiation treatment for head and neck cancer.Says it also reduces the cumulative renal toxicity associated with the repeated administration of cisplatin in patients with advanced ovarian cancer.

Redhill Biopharma Ltd acquires option for Phase II pancreatic cancer drug RP101

Wednesday, 13 Aug 2014 10:15am EDT

Redhill Biopharma Ltd:Announced that they have entered into a binding exclusive option agreement for the acquisition of the oncology drug candidate RP101 and next generation compounds.Under the terms of the agreement, RedHill has the option to acquire the worldwide exclusive rights to RP101 for all indications, other than to the pancreatic cancer indication in South Korea.Agreed to pay RESprotect for a one year option, which may be extended by RedHill under certain agreed terms.During the option period, RedHill may, at its discretion, conduct development activities with RP101.If RedHill elects to exercise the option, it will acquire the exclusive rights to RP101 for a total payment, for both the option and the acquisition of the rights, of $100,000, as well as potential milestone payments and tiered royalties on net revenues, ranging from single-digit to mid-teens.

Uniqure NV acquires InoCard GmbH

Monday, 11 Aug 2014 04:35pm EDT

Uniqure NV:Announced that the acquisition of InoCard GmbH, an early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.Under the terms of the agreement, InoCard shareholders will receive an upfront payment of 3 mln Euros, and certain success-based milestones and royalties.

Oncothyreon Inc announces acquisition of Alpine Biosciences

Monday, 11 Aug 2014 04:00pm EDT

Oncothyreon Inc:Acquires Alpine Biosciences, Inc., of Seattle, Washington, privately held biotechnology company developing protocells, nanoparticle platform technology designed to enable the targeted delivery of multiple therapeutic agents, including nucleic acids, proteins, peptides and small molecules.Oncothyreon intends to utilize protocell technology to develop new product candidates for the treatment of cancer and rare diseases, either on own or with partners.Upon closing of the transaction, Oncothyreon issued about 9.3 mln shares of Oncothyreon common stock in exchange for all of outstanding stock of Alpine Biosciences.Issued shares represent about ten percent of Oncothyreon's fully-diluted common stock on a post-transaction basis.Shares are subject to certain resale restrictions.Based on closing price of Oncothyreon shares on Aug. 08, 2014, merger consideration is valued at about $27 mln.

Intrexon Corp completes acquisition of Trans Ova Genetics LC

Monday, 11 Aug 2014 08:45am EDT

Intrexon Corp:Completed the acquisition of Trans Ova Genetics, L.C., a provider of bovine reproductive technologies.Under the terms of the agreement, Trans Ova stockholders received $60 million in cash, $30 million in Intrexon common stock, and $20 million in deferred payments to be paid in three equal installments upon the first, second, and third anniversaries of the closing date.

tella Inc to acquire insurance company

Tuesday, 5 Aug 2014 03:20am EDT

tella Inc:To acquire 4,000 shares (100 pct stake) of Mini-Insurer, a Tokyo-based insurance company, engaged in short-term insurance business, from eight companies and four individuals, for 40 million yen on Aug. 5.

Evolva Holding SA announces acquisition of Prosarix Ltd.

Monday, 4 Aug 2014 01:01am EDT

Evolva Holding SA:Says announces acquisition of Cambridge, UK based Prosarix Ltd., in-silico modelling company.Says will purchase Prosarix with shares.Says Prosarix shareholders will receive 1.2 million Evolva shares upfront (0.4 pct of Evolva's issued capital).Says Prosarix acquisition has no impact on Evolva's financial guidance for 2014.Prosarix shareholders are further entitled to 2 million (0.7 pct) additional Evolva shares between 2015 and 2018, linked to certain conditions.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.